Literature DB >> 33415423

Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level.

Warren Fingrut1, Arjun Law1, Wilson Lam1, Fotios V Michelis1, Auro Viswabandya1, Jeffrey H Lipton1, Rajat Kumar1, Jonas Mattsson1, Dennis Dong Hwan Kim2.   

Abstract

Allogeneic hematopoietic stem cell transplantation (HCT) is associated with significant morbidity and mortality. Elevated pre-transplant ferritin level (ferritinPre-HCT) is reported to be associated with increased mortality following HCT. The present study attempted to determine whether post-transplant ferritin level (ferritinPost-HCT) is associated with outcomes post-HCT, especially in the subgroups which developed acute or chronic graft-versus-host disease (GVHD). Out of 229 patients with serum ferritin level measured post-HCT, median ferritinPost-HCT was 2178 ng/mL. Patients were stratified into low- or high-risk groups using recursive partitioning, based on ferritinPost-HCT (≤ 3169 vs > 3169 ng/mL) and ferritinPre-HCT (≤ 669 vs > 669 ng/mL). Compared to the low ferritinPost-HCT group, the high ferritinPost-HCT group had lower 3-year overall survival (OS) (40.0% vs 66.7%, p < 0.001) and higher non-relapse mortality (NRM) (48.6% vs 17.8%, p < 0.001), but no difference in relapse (10.5% vs 19.7%, p = 0.079). Multivariate analysis confirmed ferritinPost-HCT as an independent prognostic factor for OS (p = 0.001, HR = 2.323) and NRM (p < 0.001, HR = 3.905). However, ferritinPre-HCT did not stratify well for OS or NRM. FerritinPost-HCT was also found to be an independent prognostic marker for OS and NRM in the subgroups which developed GVHD. In our cohort, high ferritinPost-HCT levels were significantly associated with decreased OS and increased NRM independent of ferritinPre-HCT or GVHD. Additional studies including larger sample sizes and prospective investigation are warranted to clarify the prognostic significance and pathophysiology of pre- and post-transplant hyperferritinemia.

Entities:  

Keywords:  Biomarker; Ferritin; Graft-versus-host disease; Mortality; Prognosis; Prognostic marker; Survival

Mesh:

Substances:

Year:  2021        PMID: 33415423     DOI: 10.1007/s00277-020-04363-1

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  6 in total

Review 1.  Biomarkers for posttransplantation outcomes.

Authors:  Sophie Paczesny
Journal:  Blood       Date:  2018-04-05       Impact factor: 22.113

2.  Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302).

Authors:  Takayoshi Tachibana; Junya Kanda; Shinichiro Machida; Takeshi Saito; Masatsugu Tanaka; Yuho Najima; Satoshi Koyama; Takuya Miyazaki; Eri Yamamoto; Masahiro Takeuchi; Satoshi Morita; Yoshinobu Kanda; Heiwa Kanamori; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2018-01-05       Impact factor: 2.490

3.  How to manage iron toxicity in post-allogeneic hematopoietic stem cell transplantation?

Authors:  George J Kontoghiorghes
Journal:  Expert Rev Hematol       Date:  2020-02-08       Impact factor: 2.929

4.  Prognostic impact of iron parameters in patients undergoing allo-SCT.

Authors:  G N Bazuaye; G N Bazuave; A Buser; S Gerull; A Tichelli; M Stern
Journal:  Bone Marrow Transplant       Date:  2011-03-14       Impact factor: 5.483

5.  One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation.

Authors:  Adlette Inati; Mario Kahale; Nada Sbeiti; Maria Domenica Cappellini; Ali T Taher; Suzanne Koussa; Therese A Nasr; Khaled M Musallam; Hussein A Abbas; John B Porter
Journal:  Pediatr Blood Cancer       Date:  2016-08-31       Impact factor: 3.167

6.  The role of liver biopsy in the workup of liver dysfunction late after SCT: is the role of iron overload underestimated?

Authors:  G T Sucak; Z A Yegin; Z N Ozkurt; S Z Aki; T Karakan; G Akyol
Journal:  Bone Marrow Transplant       Date:  2008-07-07       Impact factor: 5.483

  6 in total
  2 in total

1.  Erythroferrone and hepcidin as mediators between erythropoiesis and iron metabolism during allogeneic hematopoietic stem cell transplant.

Authors:  Michelle Pirotte; Marianne Fillet; Laurence Seidel; Aurélie Jaspers; Fréderic Baron; Yves Beguin
Journal:  Am J Hematol       Date:  2021-08-24       Impact factor: 13.265

2.  ABO Mismatch in Allogeneic Hematopoietic Stem Cell Transplant: Effect on Short- and Long-term Outcomes.

Authors:  Caterina Giovanna Valentini; Elisabetta Metafuni; Lorenzo Gallo; Sabrina Giammarco; Nicoletta Orlando; Maria Bianchi; Simona Sica; Andrea Bacigalupo; Patrizia Chiusolo; Luciana Teofili
Journal:  Transplant Direct       Date:  2021-07-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.